The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

Pfizer's Albert Bourla told investors that major drugmakers are "ready to to roll up their sleeves" and build out more direct ...

Novo Nordisk, the Danish maker of the wildly popular Ozempic and Wegovy drugs used for weight loss, was downgraded due to ...

In their zeal to “Make America Healthy Again,” Trump administration officials are making statements that some advocacy and ...

Novo Nordisk A/V (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is ...

UBS downgraded its rating of Novo to "neutral" from "buy" and lowered its 12-month price target to 340 Danish krone from 600 Danish krone. Copenhagen-listed shares in Novo, which have slumped by more ...

Breast cancer is the most common cancer in women in the U.S., with the exception of skin cancers, according to the American Cancer Society.

Choice of therapy to control high blood sugar may affect survival among older adults with cancer and type 2 diabetes, according to study results.Those who used GLP-1 receptor agonists exhibited ...

Newcomers will not only be plugging into UPS while its forward-looking yield stands at 7.4%, but while the stock's priced ...

The majority of State Health Plan participants will become eligible in October for "an innovative no-cost surgical benefit" through a new partnership with a Dallas- based healthcare network. Treasurer ...

IBSRELA generated net sales revenue of $65.0 million; XPHOZAH generated net sales revenue of $25.0 million Company ends Q2 with $238.5 million in cash, cash equivalents and investments Company raises ...